EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Prospective validation of the modified metastatic colorectal cancer score ( mCCS ) in >600 patients with RAS ‐wild‐type metastatic colorectal cancer treated with first‐line panitumumab plus FOLFIRI / FOLFOX : Final results of the non‐interventional study VALIDATE

Karin Potthoff, Jens Uhlig, Lutz Jacobasch, Lothar Müller, Marcel Reiser, Rebecca de Buhr, Silke Polata, Armin Gerger, Viktor Zehrer, Arno Amann, Thomas Göhler, Laura Serrer und 8 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70139 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Karin Potthoff und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, iOMEDICO, Freiburg, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AMGEN GmbH, AMGEN Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Existing prognostic scores for metastatic colorectal cancer (mCRC) are based on randomized clinical trial data and focus on parameters evaluated at the start of first‐line (1L) treatment. Unlike these, the modified mCRC prognostic score (mCCS) was developed using real‐world data from the German tumor registry colorectal cancer (TKK) and is based on pre‐1L treatment information. It predicts overall survival (OS) for patients with RAS ‐wild‐type (WT) mCRC using five tumor characteristics identified as independent negative prognostic factors. The mCCS aims to facilitate risk‐based treatment approaches and optimize mCRC treatment. The VALIDATE study was a prospective, non‐interventional study designed to validate the modified mCCS, recruiting patients with RAS ‐WT mCRC in Germany and Austria. A total of 646 patients from 113 study sites were enrolled in VALIDATE and received 1L therapy with panitumumab in combination with FOLFOX/FOLFIRI. Patients were categorized into risk groups according to the modified mCCS. The prognostic value of the modified mCCS was prospectively validated by demonstrating significantly longer median OS of patients in the low‐risk group (29.1 months [25.9, 32.1]) compared to those in the high‐risk group (20.1 months, [15.0, 23.9]). Rates of secondary resections of metastases were ≥ 23% for low and intermediate‐risk patients, indicating a pivotal opportunity for improved prognosis. During panitumumab administration, patient‐reported quality of life was preserved, and the tolerability profile was manageable with no new safety signals. The modified mCCS could serve as a practical tool for oncologists in routine clinical practice to aid in treatment decision‐making and effectively communicating prognosis to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansLeucovorinFluorouracilPanitumumabMaleFemaleMiddle AgedProspective StudiesCamptothecinAgedPrognosisOrganoplatinum CompoundsAdultGermanyNeoplasm MetastasisAged, 80 and overAntibodies, Monoclonalras Proteins

Stichwörter der Autor:innen

GermanyWT mCRCmCCSnon‐interventional studypanitumumabprognostic scorereal‐world data

Substanzen

LeucovorinFluorouracilPanitumumabCamptothecinOrganoplatinum CompoundsAntibodies, Monoclonalras Proteins

Autor:innen und Institutionen

  • Medical Department, iOMEDICO, Freiburg, Germany.
  • Onkologie, Praxis Dr. Med. Jens Uhlig, Naunhof, Germany.
  • Gemeinschaftspraxis Hämatologie - Onkologie, Dresden, Germany.
  • Onkologie UnterEms, Leer, Germany.
  • Praxis Internistischer Onkologie und Hämatologie, Köln, Germany.
  • Evangelisches Waldkrankenhaus Spandau, Innere Medizin I, Berlin, Germany.

ORCID-Profile: Gerald Prager, Norbert Marschner

Förderung

  • AMGEN GmbH
  • AMGEN Germany

Zitieren

APA

Potthoff, K., Uhlig, J., Jacobasch, L., Müller, L., Reiser, M., de Buhr, R., Polata, S., Gerger, A., Zehrer, V., Amann, A., Göhler, T., Serrer, L., Schröder, J., Semsek, D., Köhler, A., Stübs, P., Prager, G., Siebenbach, H. U., Schuch, A., & Marschner, N. (2026). Prospective validation of the modified metastatic colorectal cancer score ( mCCS ) in >600 patients with RAS ‐wild‐type metastatic colorectal cancer treated with first‐line panitumumab plus FOLFIRI / FOLFOX : Final results of the non‐interventional study VALIDATE. International Journal of Cancer. https://doi.org/10.1002/ijc.70139

Vancouver

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, de Buhr R, et al. Prospective validation of the modified metastatic colorectal cancer score ( mCCS ) in >600 patients with RAS ‐wild‐type metastatic colorectal cancer treated with first‐line panitumumab plus FOLFIRI / FOLFOX : Final results of the non‐interventional study VALIDATE. International Journal of Cancer. 2026. doi:10.1002/ijc.70139

BibTeX
@article{Potthoff2026,
  author = {Potthoff, Karin and Uhlig, Jens and Jacobasch, Lutz and Müller, Lothar and Reiser, Marcel and de Buhr, Rebecca and Polata, Silke and Gerger, Armin and Zehrer, Viktor and Amann, Arno and Göhler, Thomas and Serrer, Laura and Schröder, Jan and Semsek, Dieter and Köhler, Andreas and Stübs, Patrick and Prager, Gerald and Siebenbach, Hans Ulrich and Schuch, Anita and Marschner, Norbert},
  title = {Prospective validation of the modified metastatic colorectal cancer score ( mCCS ) in >600 patients with RAS ‐wild‐type metastatic colorectal cancer treated with first‐line panitumumab plus FOLFIRI / FOLFOX : Final results of the non‐interventional study VALIDATE},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70139}
}
Kostenlos starten →